Literature DB >> 34117277

Family history of early onset acute lymphoblastic leukemia is suggesting genetic associations.

Xinjun Li1, Kristina Sundquist1,2,3, Jan Sundquist1,2,3, Asta Försti1,4,5, Kari Hemminki6,7,8.   

Abstract

Childhood acute lymphoblastic leukemia (ALL) has an origin in the fetal period which may distinguish it from ALL diagnosed later in life. We wanted to test whether familial risks differ in ALL diagnosed in the very early childhood from ALL diagnosed later. The Swedish nation-wide family-cancer data were used until year 2016 to calculate standardized incidence ratios (SIRs) for familial risks in ALL in three diagnostic age-groups: 0-4, 5-34 and 35 + years. Among 1335 ALL patients diagnosed before age 5, familial risks were increased for esophageal (4.78), breast (1.42), prostate (1.40) and connective tissue (2.97) cancers and leukemia (2.51, ALL 7.81). In age-group 5-34 years, rectal (1.73) and endometrial (2.40) cancer, myeloma (2.25) and leukemia (2.00, ALL 4.60) reached statistical significance. In the oldest age-group, the only association was with Hodgkin lymphoma (3.42). Diagnostic ages of family members of ALL patients were significantly lower compared to these cancers in the population for breast, prostate and rectal cancers. The patterns of increased familial cancers suggest that BRCA2 mutations could contribute to associations of ALL with breast and prostate cancers, and mismatch gene PMS2 mutations with rectal and endometrial cancers. Future DNA sequencing data will be a test for these familial predictions.

Entities:  

Year:  2021        PMID: 34117277     DOI: 10.1038/s41598-021-90542-7

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  1 in total

1.  Familial risks for childhood acute lymphocytic leukaemia in Sweden and Finland: far exceeding the effects of known germline variants.

Authors:  Elham Kharazmi; Miguel I da Silva Filho; Eero Pukkala; Kristina Sundquist; Hauke Thomsen; Kari Hemminki
Journal:  Br J Haematol       Date:  2012-10-01       Impact factor: 6.998

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.